TSWM
ORKA

Tyler-Stone Wealth Management’s Oruka Therapeutics ORKA Stock Holding History

Tyler-Stone Wealth Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed – – 963
2021
Q4 		$0 Buy
+4
New +$121 ﹤0.01% 940

Other funds holding ORKA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Tyler-Stone Wealth Management's ORKA Position: Q1 2022 in Review

Tyler-Stone Wealth Management sold out of Oruka Therapeutics (ORKA) in Q1 2022, closing a stake of 4 shares.

Tyler-Stone Wealth Management first reported a position in ORKA in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 22 funds tracked by Wall St. Rank hold ORKA as of Q1 2022.

  • Tyler-Stone Wealth Management reported no remaining Oruka Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Tyler-Stone Wealth Management sold 4 Oruka Therapeutics shares in Q1 2022.
  • Tyler-Stone Wealth Management first reported a position in Oruka Therapeutics in Q4 2021 and held it in 1 quarter.
  • Tyler-Stone Wealth Management's Oruka Therapeutics position peaked at $0 in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2022.

Based on Tyler-Stone Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.